Cyclopharm trades at $0.99 vs $1.18 fair value with 85% global market share in lung imaging, 29% revenue CAGR projected through US expansion
View noteHold rating with $7.84 fair value vs $7.37 current price. Strong execution capabilities offset by inevitable margin compression as housing shortage normalises.
View noteProfitable biotech rarity with 90% EPP monopoly and transformational vitiligo opportunity. Fair value $19.94 vs current $10.89 implies 83% upside. Quality score 7.9/10.
View noteHOLD rating with $3.25 fair value vs $4.08 current price. 20% downside risk from premium valuation and unsustainable 0.61x distribution coverage.
View noteComputershare trades near $17.95 fair value with 37.7% EBITDA margins facing compression to 33% over 3-5 years. Quality defensive business with 5.5% yield.
View noteHOLD rating on Coles Group at $23.20 vs $23.35 fair value. Defensive duopoly position with 28% market share faces ACCC penalties and Amazon entry risk.
View noteHOLD rating with NZ$5.60 fair value vs NZ$8.43 current price. 87% market share infrastructure monopoly facing 2028 regulatory reset risks and margin compression pressures.
View noteAlternative asset manager trading at $1.98 vs $2.66 fair value. Strong fundamentals with 14.2% ROIC, 33.4% EBITDA margins, defensive 75% recurring revenues.
View noteSELL rating with $5.20 fair value vs $12.51 current price. Industry-leading AISC of $1,468/oz but trading at 18.6x EV/EBITDA versus peer median 8.5x.
View noteCharter Hall Group analysis reveals 50% overvaluation with fair value $11.04 vs current $22.01, facing competitive threats and margin compression despite market leadership.
View noteHold rating with $7.80 fair value vs $8.14 current price. 98% renewable portfolio, 20% market share, 8.4% revenue CAGR, but execution risks from $3.1bn concurrent initiatives.
View noteHOLD rating with $10.31 fair value vs $15.62 current price. Strong market leadership offset by 36% overvaluation and execution risk across multiple strategic initiatives.
View note